JAK Inhibitor VTE Risk — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Stop tofacitinib and arrange urgent thrombosis and rheumatology assessment
A new VTE during JAK-inhibitor therapy requires cessation and urgent clinical review. The thrombus is treated conventionally and future inflammatory-arthritis therapy is selected after reassessing VTE, cardiovascular and malignancy risk across the class.
Reference: MHRA: tofacitinib — measures to minimise venous-thromboembolism risk (Published March 2020): https://www.gov.uk/drug-safety-update/tofacitinib-xeljanz-new-measures-to-minimise-risk-of-venous-thromboembolism-and-of-serious-and-fatal-infections; MHRA: JAK inhibitors — measures to reduce cardiovascular, malignancy, VTE, infection and mortality risks (Published April 2023): https://www.gov.uk/drug-safety-update/janus-kinase-jak-inhibitors-new-measures-to-reduce-risks-of-major-cardiovascular-events-malignancy-venous-thromboembolism-serious-infections-and-increased-mortality